Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Revelation Biosciences, Inc. (REVB : NSDQ)
 
 • Company Description   
Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company's product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra Acquisition Inc., is based in NEW YORK.

Number of Employees: 14

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.57 Daily Weekly Monthly
20 Day Moving Average: 331,596 shares
Shares Outstanding: 15.08 (millions)
Market Capitalization: $8.55 (millions)
Beta: 2.70
52 Week High: $11.29
52 Week Low: $0.55
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -55.70% -50.11%
12 Week -67.23% -63.97%
Year To Date -94.44% -92.68%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4660 LAJOLLA VILLAGE DRIVE SUITE 100
-
SAN DIEGO,CA 92122
USA
ph: 650-800-3717
fax: -
None http://www.revbiosciences.com
 
 • General Corporate Information   
Officers
James Rolke - Chief Executive Officer
George Tidmarsh - Chairman
Chester S. Zygmont - Chief Financial Officer
Jennifer Carver - Director
Jess Roper - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 76135L101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 15.08
Most Recent Split Date: (:1)
Beta: 2.70
Market Capitalization: $8.55 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.57 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -12.04
12/31/21 - -3.16
09/30/21 - -3.43
Current Ratio
03/31/22 - 0.97
12/31/21 - 0.02
09/30/21 - 0.01
Quick Ratio
03/31/22 - -
12/31/21 - 0.02
09/30/21 - 0.01
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -0.01
12/31/21 - -4.30
09/30/21 - -0.73
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©